Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 2/20 | 0.44 |
| ▸ | GSK3B | P49841 | 2/20 | 0.41 |
| ▸ | CACNA1G | O43497 | 5/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7424821 | 0.98 | HRH3 (0.59) | HRH3L3MBTL1ELANEGSK3BCACNA1G | |
| SCHEMBL7424959 | 0.97 | HRH3 (0.57) | HRH3L3MBTL1ELANEGSK3BCACNA1G | |
| SCHEMBL3384305 | 0.86 | HRH3 (0.62) | HRH3GSK3BCACNA1GCYP2C9KCNH2 | |
| Potassium Ion SCHEMBL7427991 | 0.83 | HRH3 (0.56) | HRH3L3MBTL1ELANEGSK3BCACNA1G | |
| Potassium Ion SCHEMBL7424963 | 0.83 | HRH3 (0.56) | HRH3L3MBTL1ELANEGSK3BCACNA1G | |
| SCHEMBL7421852 | 0.82 | HRH3 (0.59) | HRH3ELANEGSK3BCACNA1GKCNH2 | |
| SCHEMBL7427115 | 0.81 | HRH3 (0.57) | HRH3ELANEGSK3BCACNA1GKCNH2 | |
| SCHEMBL3387830 | 0.80 | HRH3 (0.57) | HRH3ELANECACNA1GKCNH2RAB9A | |
| SCHEMBL7425000 | 0.80 | DRD4 (0.51) | HRH3CACNA1GKMT2ASMN1; SMN2 | |
| SCHEMBL12965742 | 0.80 | GSK3B (0.48) | HRH3ELANEGSK3BCACNA1GKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200231569-A1 | 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2020-07-23 | — | — | US | disclosed |
| EP-1771432-B1 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS AS HISTAMINE H3 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-08 | — | — | EP | disclosed |
| US-20080317671-A1 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS | CARRUTHERS NICHOLAS I | 2008-12-25 | — | — | US | disclosed |
| US-7429659-B2 | Furan compounds as histamine H3 modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-09-30 | — | — | US | disclosed |
| EP-1771432-A2 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS AS HISTAMINE H3 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-11 | — | — | EP | disclosed |
| WO-2005096734-A2 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS AS HISTAMINE H3 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-10-20 | — | — | WO | disclosed |
| US-20050222129-A1 | Non-imidazole heterocyclic compounds | JANSSEN PHARMACEUTICAL, N.V. (BE) | 2005-10-06 | — | — | US | disclosed |
| CN-1278820-A | Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase | GLAXO GROUP LTD (GB) | 2001-01-03 | — | — | CN | disclosed |
| EP-1003748-A2 | PYRROLOPYRROLONE DERIVATIVES AS INHIBITORS OF NEUTROPHIL ELASTASE | GLAXO GROUP LIMITED (GB) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999012933-A2 | PYRROLOPYRROLONE DERIVATIVES AS INHIBITORS OF NEUTROPHIL ELASTASE | GLAXO GROUP LIMITED (GB) | 1999-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222129-A1 | Non-imidazole heterocyclic compounds | HRH3, HRH4, HRH2 | HRH3 1/4885L3MBTL1 2056/4885ELANE 1752/4885 |
| US-20080317671-A1 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS | HRH3, HRH4, HRH2 | HRH3 1/4885L3MBTL1 2056/4885ELANE 1752/4885 |
| US-20200231569-A1 | 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | XDH, H1-0, RXFP1 | HRH3 564/4885L3MBTL1 4379/4885ELANE 3010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.